Cargando…
Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717850/ https://www.ncbi.nlm.nih.gov/pubmed/26493273 http://dx.doi.org/10.1111/jcmm.12704 |
_version_ | 1782410699049271296 |
---|---|
author | Doronin, Vasilii B. Parkhomenko, Taisiya A. Korablev, Alexey Toporkova, Ludmila B. Lopatnikova, Julia A. Alshevskaja, Alina A. Sennikov, Sergei V. Buneva, Valentina N. Budde, Thomas Meuth, Sven G. Orlovskaya, Irina A. Popova, Nelly A. Nevinsky, Georgy A. |
author_facet | Doronin, Vasilii B. Parkhomenko, Taisiya A. Korablev, Alexey Toporkova, Ludmila B. Lopatnikova, Julia A. Alshevskaja, Alina A. Sennikov, Sergei V. Buneva, Valentina N. Budde, Thomas Meuth, Sven G. Orlovskaya, Irina A. Popova, Nelly A. Nevinsky, Georgy A. |
author_sort | Doronin, Vasilii B. |
collection | PubMed |
description | Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to assess the production of catalytically active immunoglobulin G (IgG) antibodies or abzymes which have been shown to be present in sera of patients with several autoimmune diseases. Here, we show that IgGs from the sera of control C57BL/6 mice are catalytically inactive. During development of EAE, a specific reorganization of the immune system of mice occurred leading to a condition which was associated with the generation of catalytically active IgGs hydrolysing DNA, myelin basic protein (MBP) and MOG which was associated with increased proteinuria, changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen and thymus as well as a significant suppression of cell apoptosis in these organs. The strongest alterations were found in the early disease phase (18–24 days after immunization) and were less pronounced in later EAE stages (40 days after EAE induction). We conclude that a significant increase in DNase and proteolytic activities of antibodies may be considered the earliest statistically significant marker of MOG‐induced EAE in mice. The possible differences in immune system reorganizations during preclinical phases of the disease, acute and late EAE, leading to production of different auto‐antibodies and abzymes as well other changes are discussed. |
format | Online Article Text |
id | pubmed-4717850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47178502016-01-26 Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein Doronin, Vasilii B. Parkhomenko, Taisiya A. Korablev, Alexey Toporkova, Ludmila B. Lopatnikova, Julia A. Alshevskaja, Alina A. Sennikov, Sergei V. Buneva, Valentina N. Budde, Thomas Meuth, Sven G. Orlovskaya, Irina A. Popova, Nelly A. Nevinsky, Georgy A. J Cell Mol Med Original Articles Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to assess the production of catalytically active immunoglobulin G (IgG) antibodies or abzymes which have been shown to be present in sera of patients with several autoimmune diseases. Here, we show that IgGs from the sera of control C57BL/6 mice are catalytically inactive. During development of EAE, a specific reorganization of the immune system of mice occurred leading to a condition which was associated with the generation of catalytically active IgGs hydrolysing DNA, myelin basic protein (MBP) and MOG which was associated with increased proteinuria, changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen and thymus as well as a significant suppression of cell apoptosis in these organs. The strongest alterations were found in the early disease phase (18–24 days after immunization) and were less pronounced in later EAE stages (40 days after EAE induction). We conclude that a significant increase in DNase and proteolytic activities of antibodies may be considered the earliest statistically significant marker of MOG‐induced EAE in mice. The possible differences in immune system reorganizations during preclinical phases of the disease, acute and late EAE, leading to production of different auto‐antibodies and abzymes as well other changes are discussed. John Wiley and Sons Inc. 2015-10-23 2016-01 /pmc/articles/PMC4717850/ /pubmed/26493273 http://dx.doi.org/10.1111/jcmm.12704 Text en © 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Doronin, Vasilii B. Parkhomenko, Taisiya A. Korablev, Alexey Toporkova, Ludmila B. Lopatnikova, Julia A. Alshevskaja, Alina A. Sennikov, Sergei V. Buneva, Valentina N. Budde, Thomas Meuth, Sven G. Orlovskaya, Irina A. Popova, Nelly A. Nevinsky, Georgy A. Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title | Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title_full | Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title_fullStr | Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title_full_unstemmed | Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title_short | Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein |
title_sort | changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in eae mice treated with myelin oligodendrocyte glycoprotein |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717850/ https://www.ncbi.nlm.nih.gov/pubmed/26493273 http://dx.doi.org/10.1111/jcmm.12704 |
work_keys_str_mv | AT doroninvasiliib changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT parkhomenkotaisiyaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT korablevalexey changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT toporkovaludmilab changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT lopatnikovajuliaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT alshevskajaalinaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT sennikovsergeiv changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT bunevavalentinan changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT buddethomas changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT meuthsveng changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT orlovskayairinaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT popovanellya changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein AT nevinskygeorgya changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein |